Risperidone long‐acting injection and 1‐year rehospitalization rate of schizophrenia patients: A retrospective cohort study

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 69, Iss. 8, 2015-08 ,pp. : 497-503

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry

By Olivares J. M.   Peuskens J.   Pecenak J.   Resseler S.   Jacobs A.   Akhras K. S.  

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2197-2206

Informa Healthcare

Access to resources Recommend Favorite

Post‐Injection Delirium/Sedation Syndrome after Olanzapine Long‐Acting Intramuscular Injection – Who is at Risk?

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 3, 2015-09 ,pp. : 213-214

John Wiley & Sons Inc

Access to resources Recommend Favorite

“Impact of drug‐reimbursement policies on prescribing: A case‐study of a newly marketed long‐acting injectable antipsychotic among relapsed schizophrenia patients”

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 27, Iss. 1, 2018-01 ,pp. : 95-104

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy

By Case Michael G.   Karagianis Jamie L.   Schuh Kory J.   Hoffmann Vicki Poole  

Current Medical Research and Opinion, Vol. 29, Iss. 11, 2013-11 ,pp. : 1533-1537

Informa Healthcare

Access to resources Recommend Favorite